TriangleFHD-286 + Decitabine/Venetoclax (NCT07283094)
FHD-286 + Decitabine/Venetoclax trial for Acute Myeloid Leukemia and Myelodysplastic Syndrome (NCT07283094). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for acute myeloid leukemia in adults, either newly diagnosed with adverse risk, or progressed after one earlier treatment.
The idea: add FHD-286 to decitabine and venetoclax. Decitabine is injected under the skin each week. Venetoclax is a tablet, and FHD-286 is a capsule taken five days a week.
This phase 1 study raises the FHD-286 dose in steps and looks at safety, and plans 33 patients. At Montefiore Medical Center in the Bronx, New York, Mendel Goldfinger leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.